Grand Pharma’s nebulized RSV candidate GPN01564 cleared for Phase I trial

November 20, 2026  Source: drugdu 36

"/
On November 19, Grand Pharma announced that China’s National Medical Products Administration had cleared its in-house nebulized candidate GPN01564 for a Phase I clinical study in respiratory syncytial virus (RSV). The company reported favorable drug development characteristics, safety and efficacy in preclinical studies.

Source: http://finance.eastmoney.com/a/202611193935308279.html

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.